This study seeks to demonstrate the efficacy and safety of a cost- effective and convenient treatment regimen for the delivery of aerosol tobramycin to patients with CF who are chronically colonized with P. aeruginosa, and who have evidence of moderate-severe obstructive airway disease. Specifically, this project attempts to answer the following questions: Is the administration of tobramycin (300 mg) by inhalation twice daily for 28 days efficacious and safe in patients with CF who are chronically colonized with P. aeruginosa?
Showing the most recent 10 out of 563 publications